The FDA has just made brexanolone (Zulresso) the first medicine approved specifically for post-partum depression, a potentially devastating disorder that afflicts roughly one in every seven new mothers in the U.S., according to the American Psychological Association
Now the drug’s owner, Sage Therapeutics (NASDAQ: SAGE), of Cambridge, MA, must convince doctors to prescribe and new mothers to accept the treatment, which acts fast but requires a 60-hour continuous infusion in a health facility. The approval comes with other “black box” warnings about side effects.
Sage’s list price for brexanolone is $7,450 per vial, and it estimates a total course of… Read more »
UNDERWRITERS AND PARTNERS
